X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (1440) 1440
humans (1315) 1315
lenalidomide (1252) 1252
multiple myeloma (1147) 1147
hematology (940) 940
oncology (928) 928
multiple myeloma - drug therapy (800) 800
bortezomib (783) 783
thalidomide - analogs & derivatives (580) 580
male (576) 576
aged (572) 572
female (566) 566
thalidomide (563) 563
dexamethasone (538) 538
middle aged (528) 528
lenalidomide plus dexamethasone (523) 523
stem-cell transplantation (486) 486
antineoplastic combined chemotherapy protocols - therapeutic use (469) 469
treatment outcome (412) 412
therapy (389) 389
thalidomide - administration & dosage (372) 372
adult (369) 369
care and treatment (317) 317
survival (308) 308
antineoplastic agents - therapeutic use (306) 306
thalidomide - therapeutic use (306) 306
multiple myeloma - therapy (289) 289
chemotherapy (278) 278
dexamethasone - administration & dosage (271) 271
transplantation (268) 268
aged, 80 and over (248) 248
multiple myeloma - pathology (247) 247
cancer (241) 241
plus dexamethasone (241) 241
multiple myeloma - mortality (237) 237
recurrence (220) 220
thalidomide - adverse effects (216) 216
medicine & public health (206) 206
drug therapy (196) 196
antineoplastic combined chemotherapy protocols - adverse effects (190) 190
combination (190) 190
prognosis (187) 187
multiple myeloma - diagnosis (184) 184
open-label (179) 179
pharmacology & pharmacy (179) 179
stem cells (177) 177
elderly-patients (174) 174
disease-free survival (171) 171
low-dose dexamethasone (169) 169
hematology, oncology and palliative medicine (165) 165
patients (158) 158
analysis (156) 156
research (151) 151
combination therapy (148) 148
trial (147) 147
multiple-myeloma (145) 145
melphalan (144) 144
pomalidomide (144) 144
carfilzomib (143) 143
myeloma (143) 143
prednisone (138) 138
immunologic factors - therapeutic use (135) 135
antineoplastic agents - adverse effects (134) 134
newly-diagnosed myeloma (134) 134
transplantation, autologous (133) 133
clinical trials (130) 130
retrospective studies (130) 130
angiogenesis inhibitors (126) 126
autologous transplantation (126) 126
relapse (124) 124
refractory multiple-myeloma (121) 121
stem cell transplantation (121) 121
boronic acids - administration & dosage (120) 120
survival analysis (119) 119
cyclophosphamide (118) 118
pyrazines - administration & dosage (118) 118
clinical trials as topic (113) 113
dosage and administration (111) 111
health aspects (111) 111
risk factors (110) 110
abridged index medicus (109) 109
survival rate (109) 109
hematopoietic stem cell transplantation (106) 106
maintenance (104) 104
antineoplastic combined chemotherapy protocols - administration & dosage (103) 103
multiple myeloma - complications (102) 102
animals (101) 101
boronic acids - therapeutic use (101) 101
pyrazines - therapeutic use (100) 100
diseases (99) 99
article (98) 98
multiple myeloma - genetics (98) 98
patient outcomes (98) 98
proteasome inhibitors (98) 98
efficacy (96) 96
antineoplastic agents - administration & dosage (93) 93
follow-up studies (91) 91
immunology (90) 90
diagnosis (89) 89
dexamethasone - therapeutic use (86) 86
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1775) 1775
German (15) 15
French (13) 13
Spanish (5) 5
Russian (4) 4
Polish (3) 3
Japanese (2) 2
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Clinical Oncology, ISSN 0732-183X, 10/2010, Volume 28, Issue 30, pp. 4630 - 4634
Journal Article
Journal Article
Journal Article
GENES & DEVELOPMENT, ISSN 0890-9369, 02/2011, Volume 25, Issue 4, pp. 4630 - 4634
Purpose Cytogenetics is an important prognostic parameter in multiple myeloma (MM). Patients presenting with either t(4; 14) or del(17p) are known to have a... 
C-REACTIVE PROTEIN | MULTIPLE-MYELOMA | SURVIVAL | ABNORMALITIES | DEVELOPMENTAL BIOLOGY | CYTOGENETICS | DELETION | CELL BIOLOGY | STAGING SYSTEM | GENETICS & HEREDITY | LENALIDOMIDE | TOTAL THERAPY 3 | DURATION
Journal Article
Journal Article
Journal Article
British Journal of Haematology, ISSN 0007-1048, 07/2009, Volume 146, Issue 2, pp. 164 - 170
Journal Article
International Journal of Hematology, ISSN 0925-5710, 1/2019, Volume 109, Issue 1, pp. 79 - 90
Lenalidomide plus dexamethasone (LD) is currently the mainstay of treatment for both untreated and relapsed or refractory multiple myeloma (RRMM). Although... 
Medicine & Public Health | Hematology | Lenalidomide | Multiple myeloma | Oncology | Survival | Venous thromboembolism | Incidence | DARATUMUMAB | EVENTS | THALIDOMIDE | BORTEZOMIB | KOREA | THERAPY | EXPERIENCE | HEMATOLOGY | Health care | Dexamethasone | Medical prognosis | Medical records | Thromboembolism | Health risk assessment | Patients | Index Medicus
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 7/2016, Volume 78, Issue 1, pp. 173 - 182
Journal Article
American Journal of Hematology, ISSN 0361-8609, 10/2012, Volume 87, Issue 10, pp. 948 - 952
Journal Article
15.